Technology Appraisal Guidance on selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma released by NICE

21

Apr 2021

On March 31, 2021, NICE published Technology Appraisal Guidance on selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma (HCC).

Technology Appraisal is the only NICE program that has a direct link with the acceptance of technologies by payers. Payers need to implement the recommended technologies within three months after the publication of the guidance. Medical devices are very rarely evaluated within the Technology Appraisal program.

SIRTs are small radioactive beads that are injected into the liver's blood supply to treat liver cancer. The appraisal considered SIR-Spheres, TheraSphere, and QuiremSpheres.

NICE provided the following recommendations:

  • The SIRT SIR-Spheres and TheraSphere are recommended as an option for treating unresectable advanced HCC in adults, only if used for people with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and the companies provide SIR-Spheres or TheraSphere according to the commercial arrangements;
  • The SIRT QuiremSpheres is not recommended for treating unresectable advanced HCC in adults.

These recommendations are not intended to affect treatment with SIR-Spheres, TheraSphere, and QuiremSpheres started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place before this guidance was published until they and their NHS clinician consider it appropriate to stop.

NICE recommendations are based on the following considerations:

  • The clinical trial data for three SIRTs under the scope compared with other treatment options are limited. But, compared with sorafenib, SIRTs may have fewer and more manageable adverse effects, which can improve quality of life;
  • There is not enough evidence to consider SIRTs a cost-effective use of NHS resources for people with early and intermediate HCC;
  • For people with advanced HCC, QuiremSpheres is less clinically effective than sorafenib and costs more, so it is not recommended;
  • SIR-Spheres and TheraSphere are slightly less clinically effective than sorafenib but cost less.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

12

May 2021

The Agency for Health Technology Assessment of Andalusia Autonomous Community in Spain (AETSA) systematically evaluates healthcare technologies and provides decision-makers with critically review information about their efficacy, safety, and effectiveness. Currently, the AETSA is working on assessments of laser-induced heat therapy in epilepsy surgery, stereotactic radiation therapy for the treatment of refractory ventricular tachycardia, implantable Holter monitor with ILink Online technology for prolonged cardiac monitoring, and other topics.

Read more

10

May 2021

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 6462 of April 21, 2021, Tuscany Regional Healthcare has published assessments of six medical devices of various therapeutic areas, including devices for the treatment of vaginal prolapse, cardiovascular conditions, an implant for vocal cord rehabilitation, and a cerebral embolic protective device.

Read more

06

May 2021

The Treatment Council (Behandlingsråd) is a new model for assessing treatment methods and health technologies, expected to become fully operational during 2021. The first meeting of the Treatment Council is planned to be conducted in May 2021. On April 15, 2021, the method and process frameworks of the Treatment Council (Behandlingsråd) were sent for consultation to the parties who have previously submitted consultation responses regarding these documents.

Read more

04

May 2021

In April 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0176 and 0073 with changes to be implemented not later than August 01, 2021. Four new procedure codes related to men's health and breast surgery and one new companion diagnostic code were introduced.

Read more

30

Apr 2021

The National Institute for Health and Care Excellence (NICE) is currently developing health technology assessments concerning eHealth technologies in its Medical Technologies Guidance, Diagnostic Guidance, and Medtech Innovation Briefing programs. As of late April 2021, there are thirteen ongoing assessments.

Read more